Adamas Pharmaceuticals has announced that results of a news study for its proprietary triple combination antiviral drug (TCAD) therapy has shown improved potency novel H1N1 influenza viruses compared to other treatments.
The results of a multi-centre in vitro study of the company’s proprietary TCAD therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy. The triple combination was also shown to be active against drug-resistant flu strains.
Adamas’ TCAD therapy uses a proprietary fixed-dose combination drug product (amantadine and ribavirin), which is administered adjunctively with a neuraminidase inhibitor such as Tamiflu.
University of Alabama at Birmingham professor in the department of pediatrics Mark Prichard said that the data suggests that the triple combination of amantadine, ribavirin and oseltamivir could inhibit influenza virus replication, including the circulating novel H1N1 virus.
“The triple combination approach, because it strikes multiple targets within the viruses, might also help to prevent the development of new resistance in susceptible flu strains,” Prichard said.
During the study, researchers used a scientifically accepted in vitro infection model to compare amantadine, ribavirin and oseltamivir alone and in combination against influenza A viruses that are resistant to either oseltamivir or amantadine, including A/H1N1.
The study results showed that the triple combination was highly synergistic in vitro, and the synergy of TCAD therapy was significantly greater than the synergy of double combinations against susceptible and resistant viruses.
The study also revealed that oseltamivir and amantadine contributed to antiviral activity against oseltamivir-resistant and amantadine-resistant viruses, at concentrations where they had no activity as single agents.